About
Maxwell Biomedical is a medical technology company based in San Diego, California, founded in 2019. The company specializes in developing advanced therapies for cardiac arrhythmias, particularly atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Their flagship product, Rhythm360™, is the first implantable system designed to restore atrial function through a non-destructive, closed-loop therapy. It features four programmable therapy modes that manage atrial rhythm, including prevention, restoration, low-energy atrial cardioversion, and biatrial pacing. In 2022, Maxwell Biomedical expanded its technology portfolio by acquiring Cardialen’s assets, which include MultiPulse™ Therapy (MPT™). This therapy offers low-energy defibrillation and cardioversion for AF and ventricular tachycardia. Together with their proprietary Spatial Resynchronization Therapy (SRT™), these innovations aim to provide safer and more effective alternatives to traditional treatments. The company is committed to improving patient outcomes and is supported by a leadership team with extensive experience in the MedTech industry. Maxwell Biomedical's solutions are designed for cardiologists and healthcare providers focused on advanced treatments for heart rhythm disorders.
Technologies
Keywords
Company Information
-
Employees 11
-
Founded 2019
Location
535 Stevens Ave W, Solana Beach, California, United States, 92075-2043